Icure Pharmaceutical Incorporation (KOSDAQ: 175250)

Icure Pharmaceutical Incorporation Revenue

Icure Pharmaceutical Incorporation had revenue of 16.84B KRW in the quarter ending June 30, 2024, with 19.40% growth. This brings the company's revenue in the last twelve months to 59.84B, down -2.46% year-over-year. In the year 2023, Icure Pharmaceutical Incorporation had annual revenue of 56.81B, down -4.31%.

• Revenue (ttm): 59.84B
• Revenue Growth: -2.46%
• P/S Ratio: 1.29
• Revenue / Employee: 279.64M
• Employees: 214
• Market Cap: 76.98B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	56.81B	-2.56B	-4.31%
Dec 31, 2022	59.37B	-4.92B	-7.65%
Dec 31, 2021	64.28B	-25.86B	-28.69%
Dec 31, 2020	90.14B	29.22B	47.97%
Dec 31, 2019	60.92B	27.60B	82.84%